We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

215 hedge funds and large institutions have $3.9B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $95M | Put options by funds: $45.4M

9% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 78

5% less funds holding

Funds holding: 226215 (-11)

10% less capital invested

Capital invested by funds: $4.34B → $3.9B (-$442M)

19% less funds holding in top 10

Funds holding in top 10: 1613 (-3)

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

Holders
215
Holders Change
-11
Holders Change %
-4.87%
% of All Funds
4.34%
Holding in Top 10
13
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-18.75%
% of All Funds
0.26%
New
22
Increased
85
Reduced
78
Closed
33
Calls
$95M
Puts
$45.4M
Net Calls
+$49.5M
Net Calls Change
-$72.8M
Name Holding Trade Value Shares
Change
Change in
Stake
Russell Investments Group
76
Russell Investments Group
United Kingdom
$5.89M +$1.13M +17,182 +23%
DCM
77
DAFNA Capital Management
California
$5.5M -$197K -3,000 -3%
NHAS
78
Novo Holdings A/S
Denmark
$5.5M
Jacobs Levy Equity Management
79
Jacobs Levy Equity Management
New Jersey
$5.43M +$1.78M +27,230 +48%
WMSA
80
Weiss Multi-Strategy Advisers
New York
$5.4M -$1.18K -18 -0%
PAM
81
Panagora Asset Management
Massachusetts
$5.32M -$1.47M -22,501 -22%
PI
82
Putnam Investments
Massachusetts
$5.28M -$5.9K -90 -0.1%
California State Teachers Retirement System (CalSTRS)
83
California State Teachers Retirement System (CalSTRS)
California
$5.06M +$439K +6,698 +9%
Ameriprise
84
Ameriprise
Minnesota
$4.62M -$895K -13,656 -16%
CS
85
Credit Suisse
Switzerland
$4.51M -$726K -11,079 -14%
Axa
86
Axa
France
$4.43M -$43.1K -657 -1%
Voloridge Investment Management
87
Voloridge Investment Management
Florida
$4.36M -$1.34M -20,457 -23%
WCM Investment Management
88
WCM Investment Management
California
$4.27M +$257K +3,919 +6%
PC
89
Pier Capital
Connecticut
$4.19M -$53.3K -813 -1%
CBT
90
Capital Bank & Trust
California
$4.11M +$49.6K +757 +1%
LSA
91
L & S Advisors
California
$4.07M -$393K -6,003 -9%
New York State Common Retirement Fund
92
New York State Common Retirement Fund
New York
$3.72M +$91.8K +1,400 +3%
RhumbLine Advisers
93
RhumbLine Advisers
Massachusetts
$3.68M -$876K -13,364 -19%
First Trust Advisors
94
First Trust Advisors
Illinois
$3.67M +$305K +4,648 +9%
Schroder Investment Management Group
95
Schroder Investment Management Group
United Kingdom
$3.36M +$285K +4,355 +9%
Morgan Stanley
96
Morgan Stanley
New York
$3.29M -$2.02M -30,819 -38%
Citadel Advisors
97
Citadel Advisors
Florida
$3.22M -$16.3M -248,772 -83%
DP
98
DSAM Partners
United Kingdom
$3.19M +$3.21M +49,000 New
ORI
99
Oak Ridge Investments
Illinois
$3.06M +$3.09M +47,141 New
GAI
100
General American Investors
New York
$2.92M

BHVN Hedge Fund Activity: Q3 2020 in Review

215 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2020, worth a combined $3.9B — down 10% from $4.34B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of BHVN and 22 opened new positions — a net loss of 11 holders — while 78 trimmed existing stakes and 85 added.

The largest buyer was Capital World Investors, adding an estimated $72.8M. The largest seller was Vanguard Group, cutting an estimated $29.8M.

  • 215 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2020, down from 226 in Q2 2020.
  • Funds reported $3.9B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2020, down 10% quarter-over-quarter.
  • 22 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2020 and 33 closed out, a net change of -11 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2020 was Capital World Investors, an estimated $72.8M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2020 was Vanguard Group, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2020.